• Moderna issues a press release with “positive interim data” from its phase I trial of mRNA-1273 and plans to enter phase III by July of 2020. Stock in Moderna rises by 30%. Sources 1,2
• Moderna’s chief financial officer, Lorance Kim and its chief medical officer, Tal Zaks exercise their stock options to sell US $30 million in shares, reaping profits of US $ 16.8 million and US $8.2 million, respectively. Source
